Business Context and Reporting Period
This Form 8-K is a current report filed by NanoVibronix, Inc. (trading symbol: NAOV) on September 13, 2022. The filing addresses corporate governance matters regarding the rescheduling of the company's 2022 Annual Meeting of Stockholders. Note: The request metadata references "Envue Medical, Inc.," but the filing text explicitly identifies the registrant as NanoVibronix, Inc.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on procedural updates regarding shareholder meetings and does not contain financial performance data.
Material Changes
- Meeting Rescheduling: The 2022 Annual Meeting of Stockholders, originally scheduled for September 14, 2022, was postponed and rescheduled to December 15, 2022.
- Meeting Format: The Annual Meeting will be held virtually via remote communication.
- Record Date: The record date for stockholders entitled to vote is set as the close of business on October 17, 2022.
Guidance, Outlook, and Corporate Actions
Due to the change in the meeting date exceeding 30 days from the anniversary of the 2021 Annual Meeting, the company established new deadlines for shareholder proposals and director nominations:
- Proposal Deadline: Stockholder proposals for inclusion in proxy materials under Rule 14a-8 must be received by September 24, 2022.
- Nomination Deadline: Written notice for business proposals outside of Rule 14a-8 or director nominations must be received by September 24, 2022.
- Submission Address: 525 Executive Blvd., Elmsford, NY 10523.
The filing incorporates a press release dated September 14, 2022, as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the new Annual Meeting date of December 15, 2022, and the virtual format.
- Confirm the record date of October 17, 2022, to determine voting eligibility.
- Note the September 24, 2022, deadline for submitting shareholder proposals or director nominations.
- Review the attached press release (Exhibit 99.1) for any additional details on the postponement rationale.